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Hypoxic pulmonary hypertension is a severe syndrome
with a complex underlying pathophysiology. The mecha-
nisms which lead to hypoxic pulmonary hypertension
(HPH) remain incompletely understood and an impair-
ment of the vaso- and bronchodilatory NO-cGMP signal-
ling cascade has been suggested. Clinically, the specific
phosphodiesterase 5 inhibitor sildenafil reduces pulmo-
nary remodeling and hypoxic pulmonary resistance, but it
is unclear whether this effect is mechanisms-based, ie
PDE5 is involved in the pathophysiology of HPH. Here
we report changes in protein expression and activity of all
key enzymes of the NO-cGMP signalling cascade in lungs
of mice kept under normobaric hypoxia (10% O2) for 5
and 22 days versus normobaric controls. We also exam-
ined the effects of acute sildenafil treatment in isolated
perfused lungs following exposure to hypoxia for 5d and
the possible role of the the counter player of NO, the
superoxide generating NADPH oxidase (Nox) 4. Superox-
ide can scavenge NO to yield peroxynitrite which in turn
nitrates protein tyrosin residues; immunopositive nitroty-
rosine of cellular proteins was thus taken as a marker of
oxidative/nitrative stress. Phosphorylation of the cGK
substrate, vasodilator stimulated phosphoprotein (VASP),
was taken as an overall marker for the effectiveness of NO-
cGMP signalling. Surprisingly, NOS III and NOS II expres-
sion were significantly increased as early as 5 days of
hypoxia (192 ± 16% and 222 ± 34% of control, p < 0.01)
and remained elevated after 22 d of hypoxia (179 ± 10%
and 180 ± 7% of control, p < 0.01). Consistently, cGMP
accumulation in the perfusate of isolated lungs from mice
exposed 5d to hypoxia was significantly increased as com-
pared with normoxic lungs. In contrast, to recent studies,
we found unchanged protein expression of sGC α1/β1 and
cGMP dependent phosphodiesterase as well as sustained
basal and DEA-NO (300 µM) stimulated in vitro sGC α1/β1 activity and cGMP-dependent phosphodiesterase activ-
ity. However, protein expression of cGMP-dependent pro-
tein kinase (cGKI) was significantly decreased after 22 d of
hypoxia (83 ± 5.3 % of control, p < 0.01). The net result
of these counterveiling effects on cGMP signalling as evi-
denced by VASP phosphorylation were surprisingly
increased after 22 days of hypoxia (350 ± 84.5% of norm,
p < 0.01). Immunopositive tyrosine nitration of cellular
proteins after 5 and 22d of hypoxia were unchanged sug-
gesting that the bioavailability of NO was not affected by
reactive oxygen species and peroxynitrite formation. Also
Nox 4 expression was unchanged. Taken together, our
results suggest that NO-cGMP signalling is not primarily
affected in HPH but rather upregulated in a compensatory
fashion; thus further inhibition of cGMP degradation by
sildenafil do not target a pathomechanism per se but
enhance these auto-protective mechanisms in the setting
of HPH.
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